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Abstract: Importance: During mountain travel, patients with chronic obstructive pulmonary disease
(COPD) are at risk of experiencing severe hypoxemia, in particular, during sleep. Objective: To evaluate
whether preventive dexamethasone treatment improves nocturnal oxygenation in lowlanders with COPD
at 3100 m. Design, Setting, and Participants: A randomized, placebo-controlled, double-blind, parallel
trial was performed from May 1 to August 31, 2015, in 118 patients with COPD (forced expiratory volume
in the first second of expiration [FEV1] >50% predicted, pulse oximetry at 760 m ￿92%) who were living
at altitudes below 800 m. The study was conducted at a university hospital (760 m) and high-altitude
clinic (3100 m) in Tuja-Ashu, Kyrgyz Republic. Patients underwent baseline evaluation at 760 m, were
taken by bus to the clinic at 3100 m, and remained at the clinic for 2 days and nights. Participants were
randomized 1:1 to receive either dexamethasone, 4 mg, orally twice daily or placebo starting 24 hours
before ascent and while staying at 3100 m. Data analysis was performed from September 1, 2015, to
December 31, 2016. Interventions: Dexamethasone, 4 mg, orally twice daily (dexamethasone total daily
dose, 8 mg) or placebo starting 24 hours before ascent and while staying at 3100 m. Main Outcomes
and Measures: Difference in altitude-induced change in nocturnal mean oxygen saturation measured by
pulse oximetry (Spo2) during night 1 at 3100 m between patients receiving dexamethasone and those
receiving placebo was the primary outcome and was analyzed according to the intention-to-treat principle.
Other outcomes were apnea/hypopnea index (AHI) (mean number of apneas/hypopneas per hour of time
in bed), subjective sleep quality measured by a visual analog scale (range, 0 [extremely bad] to 100
[excellent]), and clinical evaluations. Results: Among the 118 patients included, 18 (15.3%) were women;
the median (interquartile range [IQR]) age was 58 (52-63) years; and FEV1 was 91% predicted (IQR, 73%-
103%). In 58 patients receiving placebo, median nocturnal Spo2 at 760 m was 92% (IQR, 91%-93%) and
AHI was 20.5 events/h (IQR, 12.3-48.1); during night 1 at 3100 m, Spo2 was 84% (IQR, 83%-85%) and
AHI was 39.4 events/h (IQR, 19.3-66.2) (P < .001 both comparisons vs 760 m). In 60 patients receiving
dexamethasone, Spo2 at 760 m was 92% (IQR, 91%-93%) and AHI was 25.9 events/h (IQR, 16.3-37.1);
during night 1 at 3100 m, Spo2 was 86% (IQR, 84%-88%) (P < .001 vs 760 m) and AHI was 24.7 events/h
(IQR, 13.2-33.7) (P = .99 vs 760 m). Altitude-induced decreases in Spo2 during night 1 were mitigated
by dexamethasone vs placebo by a mean of 3% (95% CI, 2%-3%), and increases in AHI were reduced by
18.7 events/h (95% CI, 12.0-25.3). Similar effects were observed during night 2. Subjective sleep quality
was improved with dexamethasone during night 2 by 12% (95% CI, 0%-23%). Sixteen (27.6%) patients
using dexamethasone had asymptomatic hyperglycemia. Conclusions and Relevance: In lowlanders in
Central Asia with COPD traveling to a high altitude, preventive dexamethasone treatment improved
nocturnal oxygen saturation, sleep apnea, and subjective sleep quality.
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Abstract
IMPORTANCE Duringmountain travel, patients with chronic obstructive pulmonary disease (COPD)
are at risk of experiencing severe hypoxemia, in particular, during sleep.
OBJECTIVE To evaluate whether preventive dexamethasone treatment improves nocturnal
oxygenation in lowlanders with COPD at 3100m.
DESIGN, SETTING, ANDPARTICIPANTS A randomized, placebo-controlled, double-blind, parallel
trial was performed fromMay 1 to August 31, 2015, in 118 patients with COPD (forced expiratory
volume in the first second of expiration [FEV1] >50% predicted, pulse oximetry at 760m92%)
whowere living at altitudes below 800m. The study was conducted at a university hospital (760m)
and high-altitude clinic (3100m) in Tuja-Ashu, Kyrgyz Republic. Patients underwent baseline
evaluation at 760m, were taken by bus to the clinic at 3100m, and remained at the clinic for 2 days
and nights. Participants were randomized 1:1 to receive either dexamethasone, 4 mg, orally twice
daily or placebo starting 24 hours before ascent and while staying at 3100m. Data analysis was
performed from September 1, 2015, to December 31, 2016.
INTERVENTIONS Dexamethasone, 4mg, orally twice daily (dexamethasone total daily dose, 8mg)
or placebo starting 24 hours before ascent and while staying at 3100m.
MAINOUTCOMESANDMEASURES Difference in altitude-induced change in nocturnal mean
oxygen saturationmeasured by pulse oximetry (SpO2) during night 1 at 3100m between patients
receiving dexamethasone and those receiving placebo was the primary outcome and was analyzed
according to the intention-to-treat principle. Other outcomes were apnea/hypopnea index (AHI)
(mean number of apneas/hypopneas per hour of time in bed), subjective sleep quality measured by
a visual analog scale (range, 0 [extremely bad] to 100 [excellent]), and clinical evaluations.
RESULTS Among the 118 patients included, 18 (15.3%) were women; themedian (interquartile range
[IQR]) age was 58 (52-63) years; and FEV1 was 91% predicted (IQR, 73%-103%). In 58 patients
receiving placebo, median nocturnal SpO2 at 760mwas 92% (IQR, 91%-93%) and AHI was 20.5
events/h (IQR, 12.3-48.1); during night 1 at 3100m, SpO2 was 84% (IQR, 83%-85%) and AHI was 39.4
events/h (IQR, 19.3-66.2) (P < .001 both comparisons vs 760m). In 60 patients receiving
dexamethasone, SpO2 at 760mwas 92% (IQR, 91%-93%) and AHI was 25.9 events/h (IQR, 16.3-37.1);
during night 1 at 3100m, SpO2 was 86% (IQR, 84%-88%) (P < .001 vs 760m) and AHI was 24.7
events/h (IQR, 13.2-33.7) (P = .99 vs 760m). Altitude-induced decreases in SpO2 during night 1 were
mitigated by dexamethasone vs placebo by a mean of 3% (95% CI, 2%-3%), and increases in AHI
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Abstract (continued)
were reduced by 18.7 events/h (95% CI, 12.0-25.3). Similar effects were observed during night 2.
Subjective sleep quality was improved with dexamethasone during night 2 by 12% (95% CI,
0%-23%). Sixteen (27.6%) patients using dexamethasone had asymptomatic hyperglycemia.
CONCLUSIONS ANDRELEVANCE In lowlanders in Central Asia with COPD traveling to a high
altitude, preventive dexamethasone treatment improved nocturnal oxygen saturation, sleep apnea,
and subjective sleep quality.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02450994
JAMA Network Open. 2019;2(2):e190067. doi:10.1001/jamanetworkopen.2019.0067
Introduction
Worldwide, millions of persons live in or travel to mountain areas.1 Even thoughmoderate hypobaric
hypoxia at altitudes of 1500 to 3500m is generally well tolerated by healthy individuals, nocturnal
hypoxemia, periodic breathing, disturbances of sleep structure, and impairment of subjective sleep
quality are commonly noticed.2 Patients with preexisting respiratory conditions, such as obstructive
sleep apnea syndrome3 or chronic obstructive pulmonary disease (COPD),4 seem to be particularly
susceptible to altitude-related hypoxemia, sleep, and breathing disturbances.5 In patients with
obstructive sleep apnea syndrome, continuous positive airway pressure therapy combined with
acetazolamide was effective in preventing exacerbation of sleep apnea and improving hypoxemia
during altitude sojourns.6 In patients with COPD, mechanical ventilatory constraints combined with
the stimulation of ventilation by acetazolamide and hypobaric hypoxia at high altitudesmay promote
dyspnea, but to our knowledge, this has not been investigated.7
The use of supplemental oxygen is hampered for logistical reasons and because its use is
cumbersome and difficult for travelers with COPD. Therefore, other means to prevent altitude-
related adverse health effects in patients with COPD are warranted. In healthy mountaineers,
dexamethasone, a drug with potent glucocorticoid action, has been shown to prevent acute
mountain sickness (AMS),8,9 reduce pulmonary artery pressure, and stimulate ventilation in
individuals susceptible to high-altitude pulmonary edema.10 In patients with COPD, glucocorticoids
are used to treat exacerbations.11 The present randomized, placebo-controlled trial was performed in
lowlanders in Central Asia with mild to moderate COPD to evaluate the hypothesis that preventive
dexamethasone treatment would mitigate nocturnal hypoxemia, periodic breathing, and
impairments of sleep quality during a stay at high altitude.
Methods
Design and Setting
This study was part of a project investigating prevention of altitude-related adverse health effects in
patients with COPD. Patient characteristics, data on AMS, and disturbances of postural control have
been reported.12,13 The present analysis of secondary end points of the randomized, double-blind,
placebo-controlled, parallel-group trial evaluates the efficacy of dexamethasone in preventing
altitude-related nocturnal hypoxemia in lowlanders with COPD traveling to and staying for 2 nights
at 3100m. The protocol was approved by the ethics committee of the National Center for Cardiology
and Internal Medicine and endorsed by the Cantonal Ethics Committee Zurich, Switzerland, and is
available in Supplement 1. Participants gave written informed consent; there was no financial
compensation. This study followed the Consolidated Standards of Reporting Trials (CONSORT) reporting
guideline.14
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FromMay 1 to August 31, 2015, participants underwent baseline examinations at the National
Center for Cardiology and Internal Medicine, Bishkek, Kyrgyz Republic, at 760 m (mean barometric
pressure, 700mmHg), then traveled by minibus within 3 to 5 hours to the High-Altitude Clinic, Tuja-
Ashu, Kyrgyz Republic, at 3100m (barometric pressure, 545mmHg) and stayed there for 2 nights.
On the day before and during altitude sojourns, participants received dexamethasone or placebo
according to randomization. For safety reasons, participants with relevant intercurrent illness, severe
hypoxemia (pulse oximetry [SpO2] <75% for >30minutes or <70% for >15minutes), or requesting to
descend to lower altitude because of discomfort received supplemental oxygen, were withdrawn
from the study, and were relocated to lower altitude.
Participants
Among outpatients of the National Center for Cardiology and Internal Medicine and other clinics of
the Bishkek area, men and women aged 20 to 75 years, with a diagnosis of grade 1 or 2 COPD
according to guidelines of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) (grade 1,
mild: postbronchodilator forced expiratory volume in the first second of expiration [FEV1]/forced
vital capacity [FVC] <0.7, FEV180%predicted; grade 2, moderate: FEV1/FVC <0.7, FEV1 50%-79%
predicted)11 and living at an altitude lower than 800mwere invited to participate. Exclusion criteria
weremore thanmild hypoxemia at 760m (SpO2 <92%); exacerbation of COPDwithin 3months
before the study; diabetes; any uncontrolled cardiovascular, neurologic, or psychiatric disease; heavy
smoking (>20 cigarettes per day); and a stay at an altitude higher than 1000m in the past month.
Interventions
Dexamethasone, 4mg, capsules or identical-looking placebo capsules were administered at
breakfast and dinner (dexamethasone total daily dose, 8mg) under supervision of one of the
investigators starting 24 hours before ascent and during the stay at 3100m.
Assessments
Amedical history was obtained and a clinical examination was performed. Symptomswere evaluated
by the COPDAssessment Test. The test contains 8 categories about COPD symptoms; each category
ranges from 0 (I am very happy) to 5 (I am very sad). A score of 5 points represents the upper limit
of normal; greater than 5 and lower than 10 indicates low effect andmost days are good; greater than
10 and less than 20 indicates medium effect and COPD is one of themost important problems that
they have; and greater than 20 indicates high effect and COPD stops them from doing most things
that they want to do.15 Respiratory sleep studies (AlicePDx; Philips AG Respironics), including SpO2,
nasal cannula pressure swings, thoracic and abdominal movements, snoring, electrocardiogram, and
body position, were performed. Indices of oxygenation and themean number of apneas/hypopneas
per hour of time in bed (apnea/hypopnea index [AHI]) were determined. Cerebral tissue oxygenation
wasmonitored with near-infrared spectroscopy sensors (NIRO 200NX; Hamamatsu Photonics)
placed bilaterally, high on the forehead.16 Subjective sleep quality was rated on a 100-mm visual
analog scale ranging from0 (extremely bad) to 100 (excellent), and insomnia was evaluated by
asking participants to estimate the number of awakenings and time spent awake at night.17 The
Karolinska Sleepiness Scale was administered (score range from 1 [extremely alert] to 9 [very sleepy,
great effort to keep alert, fighting sleep]).18 Vital signs, spirometry,19 and arterial blood gas analysis
were obtained. The reaction time was assessed by the psychomotor vigilance test.20 Assessments
are further explained in eMethods in Supplement 2.
Outcomes
The primary outcomewas the between-group difference in altitude-induced changes in mean
nocturnal SpO2 during the first night at 3100m. Secondary outcomes were effects of altitude and
dexamethasone on various clinical and physiologic measures.
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Sample Size
Sample size estimation based on the trial evaluating effects of dexamethasone on AMS indicated a
minimal number of 100 participants.12 The present trial was powered with 80% to detect a mean
(SD) minimal difference in SpO2 (primary outcome) of 2% (3.5%)
5 and, in AHI, an important
secondary outcome, of 10 (17) events/h, with a 2-sided significance level of α = .05.
Randomization
Patients were randomized by an independent person 1:1 to dexamethasone or placebo in blocks of 5,
minimizing for sex, age 50 years or younger and older than 50 years, and FEV1 less than 80%
predicted or 80% predicted and higher, using a computer algorithm.
Blinding
Identical-looking dexamethasone and placebo capsules were dispensed and labeledwith a concealed
code by an independent pharmacist. Participants and investigators were blinded to the study drug
until completion of data analysis.
Statistical Analysis
Data analysis was performed from September 1, 2015, to December 31, 2016. Data are presented as
medians (interquartile ranges) and mean differences (95% CIs). The primary outcome was analyzed
according to the intention-to-treat principle. Missing values were filled by 20 imputations using
regressionmodels with chained equations21 including the following predictors at 760m: drug
assignment, study night, anthropometrics, daytime SpO2, FEV1% predicted, and bodymass index.
Secondary outcomes were analyzed by the per-protocol approach without replacing missing values.
Between-group comparisons were performed byMann-Whitney tests and, by computing mean
differences with 95% CIs, intragroup comparisons were performed byWilcoxon signed rank tests.
Regression analyses were performed to elucidate independent predictors of outcomes at 3100m. A
2-tailed P value <.05 was considered statistically significant. The statistical analysis plan is available
in Supplement 1.
Results
A total of 294 individuals were screened, and 124 were randomized (Figure 1); 6 patients were
excluded post randomization; 4 had severe coexisting disease and 2 were living above 1500m. The
intention-to-treat analysis included 58 patients randomized to placebo and 60 randomized to
dexamethasone. Of these, 10 of 58 (17.2%) patients in the placebo group and 4 of 60 (6.7%) patients
in the dexamethasone group (P = .09 between dexamethasone and placebo, Fisher exact test) had
incomplete data for various reasons (Figure 1). Seven of 58 (12.1%) patients assigned to placebo and 1
of 60 (1.7%) assigned to dexamethasone (P = .03 between dexamethasone and placebo, Fisher
exact test) could not stay both nights at 3100m because they required oxygen and relocation to a
lower altitude according to safety rules. Adverse health effects, such as excessive hypoxemia,
elevated blood pressure, or discomfort for other reasons, resolved within a few hours without
sequelae. Among the 118 patients included, 18 (15.3%) were women; themedian (interquartile range
[IQR]) age was 58 (52-63) years; and FEV1 was 91% predicted (IQR, 73%-103%). Further
characteristics of patients receiving dexamethasone and placebo were similar (Table 1).
Table 2 and Figure 2 summarize the effects of altitude travel and dexamethasone on outcomes
assessed during sleep studies. eTable 1 and the eFigure in Supplement 2 provide additional details.
The mean nocturnal SpO2 was significantly reduced during nights 1 (84%; IQR, 83%-85%) and 2
(86%; IQR, 84%-87%) at 3100m comparedwith 760m (92%; IQR, 91%-93%). Mean reductionwith
altitude in nights 1 and 2was 8% (95%CI, 7%-9%) and 7% (95%CI, 6%-7%) in patients who received
placebo. Correspondingmean nocturnal SpO2 values in patients receiving dexamethasonewere 92%
(IQR, 91%-93%) at 760m, and 86% (IQR, 84%-88%) on night 1 and 87% (IQR, 86%-89%) on night
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2 at 3100m. Therefore, mean reductions with altitude during nights 1 and 2 were 5% (95% CI,
5%-6%) and 4% (95% CI, 4%-5%). Thus, dexamethasone attenuated the altitude-induced drop in
SpO2 by amean of 3% (95% CI, 2%-3%) during the first night and by 2% (95% CI, 1%-3%) during the
second night at 3100m (Figure 2, Table 2). In night 1 at 3100m, patients receiving dexamethasone
spent 15% (95% CI, 6%-23%) less time with SpO2 lower than 90% compared with patients receiving
placebo and in night 2 at 3100m they spent 22% (95%CI, 13%-30%) less timewith SpO2 lower than
90% compared with patients receiving placebo (Table 2). Thirty-two patients (55.2%) receiving
placebo and 15 of those receiving dexamethasone (25.0%) (χ2 test, P = .001) had amean nocturnal
SpO2 of less than 85%, which is a degree of hypoxemia considered to indicate the need for in-flight
oxygen if reached during a hypoxic challenge test performed in fitness-to-fly assessment.22
The oxygen desaturation index increased in both groups with altitude ascent; however,
dexamethasonemitigated this effect by 15.4 events/h (95% CI, 9.3-21.4) in the first night at 3100m
and by 17.7 events/h (95% CI, 9.5-21.8) in the second night at 3100 m, and it prevented an altitude-
induced increase in the AHI (median for placebo in the first night at 3100m: from 20.5 events/h [IQR,
12.3-48.1] to 39.4 events/h [IQR, 19.3-66.2]; dexamethasone: from 25.9 events/h [IQR, 16.3-37.1] to
24.7 events/h [IQR,13.2-33.7]). An increase in AHI was mainly prevented by a major increase in the
central AHI and, to a lesser extent, in the obstructive AHI. Dexamethasone significantly reduced the
nighttime spent with periodic breathing comparedwith placebo (median, 4minutes [IQR, 0-15] vs 26
minutes [IQR, 4-70]). During the first night at 3100m, patients receiving placebo developed a slight
reduction in cerebral tissue oxygenation (median, from 70% [IQR, 67%-73%] to 67% [IQR,
62%-70%]) and an increase in the cerebral oxygen desaturation index (median, from 0.7 events/h
[IQR, 0.1-2.0] to 3.6 events/h [IQR, 0.6-11.4]); similar changes were observed in the dexamethasone
Figure 1. CONSORT Flowchart
294 Patients assessed for eligibility
62 Assigned to placebo and received
treatments as allocated
58 Included in intention-to-treat
analysis
48 Included in per-protocol analysis
4 Postrandomization exclusions
4 Did not fulfill inclusion criteria
2 Postrandomization exclusions
2 Did not fulfill inclusion criteria
62 Assigned to dexamethasone and
received treatments as allocated
124 Randomized
170 Excluded
78 No COPD
47 No consent signed
19 Severe COPD
15 Severe coexisting disease
5 Heavy smoking
3 Lack of time
1 Severe hypoxemia
1 Died
1 Lack of adherence
10 Excluded
4 Received nocturnal oxygen
supplementation at 3100 m
3 Withdrew consent
2 Were relocated to lowland
due to shivering and high
temperature
1 Had very high blood pressure
60 Included in intention-to-treat
analysis
56 Included in per-protocol analysis
4 Excluded
3 Withdrew consent
1 Received nocturnal oxygen
supplementation at 3100 m
COPD indicates chronic obstructive
pulmonary disease.
JAMANetworkOpen | PulmonaryMedicine Dexamethasone and Oxygenation in Lowlanders With COPD Traveling to 3100Meters
JAMA Network Open. 2019;2(2):e190067. doi:10.1001/jamanetworkopen.2019.0067 (Reprinted) February 22, 2019 5/13
Downloaded From: https://jamanetwork.com/ by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 01/15/2020
group (cerebral tissue oxygenation: median, from 68% [IQR, 65%-74%] to 67% [IQR, 61%-72%] and
cerebral oxygen desaturation index: from 0.8 events/h [IQR, 0.1-1.9] to 2.0 events/h [IQR, 0.4-4.9])
(Table 2). At 3100 m on night 1, heart rate was increased in both groups compared with the rate at
760 m (median for placebo: from 65 bpm [IQR, 59-70] to 69 bpm [IQR, 63-73]; dexamethasone:
from 64 bpm [IQR, 60-68] to 69 bpm (IQR, 62-75]) (Table 2).
Patients receiving dexamethasone perceived better sleep quality than patients receiving
placebo (Table 2, Figure 2); mean differences with dexamethasone during nights 1 and 2 at 3100m
were 11% (95% CI, −1% to 22%) and 12% (95% CI, 0%-23%). There were no significant between-
group differences in subjective estimates of sleep latency, nocturnal time spent awake, and
awakenings. The psychomotor vigilance test reaction time and subjective sleepiness were similar at
low and high altitude and no between-group difference was noted (Table 3).
A significant increase in mean arterial blood pressure in the placebo group after night 2 at 3100
m by 3mmHg (95% CI, 1-6 mmHg), and a significant blood pressure–reducing effect of
dexamethasone at the higher altitude were observed after night 1 at 3100m by −5mmHg (95% CI,
−9 to −1 mm Hg); after night 2 at 3100 m by −3 mmHg (95% CI, −7 to 0 mmHg) (Table 3; eFigure in
Supplement 2). Arterial blood gas analyses revealed altitude-induced hypocapnia and an increase in
pH that was more pronounced in patients receiving dexamethasone who had less altitude-induced
hypoxemia than patients receiving placebo. Spirometry findings did not change over the course of
the study. Patients assigned to dexamethasone vs placebo had a higher blood glucose concentration
(median, 167.6mg/dL [IQR, 140.5-205.4] vs 133.3mg/dL [IQR, 109.9-183.2] [to convert tomillimoles
per liter, multiply by 0.0555]) (Table 3), and 16 of them (27.6%) had asymptomatic hyperglycemia
(glucose level200mg/dL).
In regression analysis, lower PaO2 (coefficient, 0.50; 95% CI, 0.17-0.84) and FEV1 (coefficient,
0.02; 95% CI, 0.00-0.04), and a higher PaCO2 (coefficient, −1.15; 95% CI, −1.89 to −0.41) and AHI
Table 1. Characteristics of the Intention-to-Treat Population Assessed at 760m
Variable
Group
All
(N = 118)
Placebo
(n = 58)
Dexamethasone
(n = 60)
Men, No. (%) 100 (84.7) 50 (86.2) 50 (83.3)
Women, No. (%) 18 (15.3) 8 (13.8) 10 (16.7)
Age, median (IQR), y 58 (52-63) 60 (53-64) 57 (50-62)
BMI, median (IQR) 25.6 (22.8-27.7) 25.5 (22.7-27.5) 25.7 (23.4-27.7)
FEV1, median (IQR), L 2.6 (2.1-3.0) 2.7 (2.2-3.0) 2.5 (1.9-3.0)
% Predicted 91 (73-103) 94 (76-103) 86 (70-104)
FVC, median (IQR), L 4.2 (3.6-4.7) 4.2 (3.6-4.9) 4.1 (3.4-4.5)
% Predicted 117 (101-129) 118 (104-134) 117 (99-125)
FEV1/FVC, median (IQR) 0.64 (0.57-0.68) 0.65 (0.60-0.68) 0.63 (0.56-0.66)
COPD, GOLD grade, No. (%)a
1 78 (66.1) 41 (70.7) 37 (61.7)
2 40 (33.9) 17 (29.3) 23 (38.3)
Pulse oximetry, median (IQR), % 95 (94-96) 95 (95-96) 95 (94-96)
Smoking, median (IQR), pack-years 20 (0-34) 24 (2-35) 20 (0-34)
NYHA classification, median (IQR)b 2 (1-2) 2 (1-2) 2 (1-2)
COPD Assessment Test score, median (IQR)c 7 (5-11) 7 (3-11) 7 (5-11)
Regular medication, No. (%)
Inhaled
β-Adrenergics 2 (1.7) 1 (1.7) 1 (1.7)
Anticholinergics 5 (4.2) 3 (5.2) 2 (3.3)
Corticosteroids 1 (0.8) 1 (1.7) 0
Antihypertensives 13 (11.0) 8 (13.8) 5 (8.3)
β-Blockers 5 (4.2) 2 (3.4) 3 (5.0)
Antidiabetics 1 (0.8) 1 (1.7) 0
Abbreviations: BMI, bodymass index (calculated as
weight in kilograms divided by height in meters
squared); COPD, chronic obstructive pulmonary
disease; FEV1, forced expiratory volume in the first
second of expiration; FVC, forced vital capacity; GOLD,
Global Initiative for Obstructive Lung Disease; IQR,
interquartile range; NYHA, New York Heart
Association.
a GOLD grade 1, mild: postbronchodilator FEV1/FVC
less than 0.7, FEV1 80% or higher than predicted;
grade 2, moderate: FEV1/FVC less than 0.7, FEV1 50%
to 79% predicted.
b New York Heart Association classification ranging
from 1 (no symptoms and no limitations) to 4 (severe
limitations).
c The COPD Assessment Test contains 8 categories
about COPD symptoms; each category ranges from
0 (I am very happy) to 5 (I am very sad). A score of 5
points represents the upper limit of normal; greater
than 5 and lower than 10 indicates low effect and
most days are good; greater than 10 and less than 20
indicatesmedium effect and COPD is one of themost
important problems that they have; and greater than
20 indicates high effect and COPD stops them from
doingmost things that they want to do.
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(coefficient, −0.03; 95% CI, −0.05 to −0.01) at 760mwere associated with lower mean nocturnal
SpO2 at 3100m (eTable 2 in Supplement 2). Furthermore, the risk of experiencing an adverse event
that required an intervention (eg, oxygen or drug therapy) and premature study termination was
increased by amean of 3.84 (95% CI, 1.28-11.11) per each 1-kPa reduction in PaO2 at 760m, and this
risk was reduced 20 times (95% CI, 4.34 to >100) by preventive dexamethasone treatment (eTable 3
in Supplement 2). In contrast to PaO2, daytime SpO2 level at 760mwas not a significant predictor of
premature study termination in the corresponding regressionmodel (eTable 4 in Supplement 2).
Discussion
This randomized, placebo-controlled, double-blind trial in lowlanders in Central Asia with mild to
moderate COPD (GOLD grade 1-2) demonstrates that preventive dexamethasone treatment
mitigated the altitude-induced decrease in the nocturnal SpO2 and prevented an increase in AHI
during 2 nights at 3100m. These favorable effects were associated with improvements in subjective
sleep quality. Therefore, dexamethasonemay be used in selected patients with COPD undergoing
high altitude travel to prevent severe nocturnal hypoxemia.
In healthy lowlanders, an altitude-dependent reduction in nocturnal SpO2, emergence of
periodic breathing, sleep disturbances, and impaired cognitive performance have been reported.2
For example, in 51 healthy lowlanders (median age, 24 years), the median nocturnal SpO2 in the night
after ascent from 490 to 2590mwas 90%, and the AHI was 13.1 events/h.24 In 40 healthy
volunteers (mean age, 40 years) ascending from 555 to 3150m, themean SpO2 during the first night
at high altitude was 83%, and the AHI was 7.4 events/h.25
Table 2. Sleep Studies and Subjective Sleep Assessment
Variable
Median (IQR)
Treatment Effect at 3100 m,
Mean Difference (95% CI)Placebo Group (n = 48) Dexamethasone Group (n = 56)
760 m
3100 m
760 m
3100 m
Night 1 Night 2Night 1 Night 2 Night 1 Night 2
Time in bed, min 545 (527 to
557)
513 (496 to
529)a
507 (484 to
521)a
533 (502 to
561)
517 (506 to
528)a
518 (502 to
530)a,b
15 (1 to
29)
20 (6 to
34)
Mean nocturnal SpO2, % 92 (91 to 93) 84 (83 to 85)a 86 (84-87)a 92 (91 to 93) 86 (84 to 88)a,b 87 (86 to 89)a,b 3 (2 to 3) 2 (1 to 3)
Time with SpO2 <90%, % of
time in bed
2 (0 to 13) 98 (97 to 99)a 96 (91 to 99)a 5 (1 to 26) 96 (90 to 98)a,b 92 (59 to 97)a,b −15 (−23 to −6) −22 (−30 to −13)
Oxygen desaturation index
(>3% dips), events/h
2.8 (0.5 to
8.1)
18.5 (6.8 to
47.0)a
20.2 (5.0 to
44.5)a
3.3 (1.6 to
7.9)
8.1 (4.3 to
20.2)a,b
7.6 (3.3 to
14.6)a,b
−15.4 (−21.4 to
−9.3)
−15.7 (−21.8 to
−9.5)
Apnea/hypopnea index,
events/h
20.5 (12.3 to
48.1)
39.4 (19.3 to
66.2)a
38.0 (15.6 to
63.2)a
25.9 (16.3 to
37.1)
24.7 (13.2 to
33.7)b
21.6 (13.4 to
38.7)b
−18.7 (−25.3 to
−12.0)
−17.7 (−24.3 to
−11.0)
Central apnea/hypopnea
index, events/h
1.6 (0.3 to
2.8)
13.2 (3.1 to
27.7)a
11.1 (2.7 to
32.1)a
1.5 (0.5 to
2.5)
3.7 (2.0 to
8.3)a,b
4.2 (1.4 to
11.8)a,b
−12.0 (−18.5 to
−5.5)
−12.1 (−18.7 to
−5.5)
Obstructive apnea/hypopnea
index, events/h
18.2 (11.1 to
38.2)
19.2 (9.3 to
35.8)
14.1 (8.6 to
36.1)
23.2 (15.6 to
36.0)
17.4 (7.1 to
24.8)a
15.6 (8.5 to
27.0)a
−6.7 (−11.5 to
−1.8)
−5.5 (−10.4 to
−0.6)
Periodic breathing, min 0 (0 to 0) 26 (4 to 70)a 22 (3 to 85)a 0 (0 to 0) 4 (0 to
15)a,b
4 (0 to
24)a,b
−40 (−63 to
−16)
−41 (−64 to
−17)
Cerebral tissue oxygen, % 70 (67 to 73) 67 (62 to 70)a NA 68 (65 to 74) 67 (61 to 72)a NA 1.0 (−2.0 to 4.0) NA
Cerebral oxygen
desaturation index, events/h
0.7 (0.1 to
2.0)
3.6 (0.6 to
11.4)a
NA 0.8 (0.1 to
1.9)
2.0 (0.4 to
4.9)a
NA −4.5 (−0.9 to
−8.1)
NA
Heart rate, bpm 65 (59 to 70) 69 (63 to 73)a 67 (60 to 72)a 64 (60 to 68) 69 (62 to 75)a 60 (54 to 67)a,b 2 (0 to 4) −5 (−8 to −3)
Subjective sleep quality, %c 58 (43 to 82) 55 (30 to 71) 55 (40 to 69) 50 (38 to 73) 57 (39 to 75) 64 (45 to 78)a,b 11 (−1 to 22) 12 (0 to 23)
Sleep latency, minc 30 (10 to 45) 30 (10 to 55) 30 (10 to 30) 30 (10 to 30) 30 (10 to 60) 30 (10 to 60) 1 (−20 to 21) −1 (−22 to 19)
Awakenings at night, No.c 2 (1 to 3) 2 (1 to 3) 2 (1 to 3) 2 (1 to 3) 2 (1 to 3) 2 (1 to 3) 0 (−1 to 1) 0 (−1 to 1)
Night-time spent awake,
minc
13 (5 to 30) 10 (5 to 25) 10 (5 to 20) 5 (5 to 15) 15 (8 to 30)a 10 (5 to 30)a 22 (−2 to 47) 5 (−20 to 30)
Abbreviations: IQR, interquartile range; NA, not assessed; SpO2, arterial oxygen
saturationmeasured by pulse oximetry.
a P < .05 vs 760m.
b P < .05 between dexamethasone and placebo at the same corresponding altitude
and day.
c Assessed subjectively. Subjective sleep quality was assessed by a 100-mm visual
analog scale ranging from0 (extremely bad) to 100 (excellent).
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In patients with COPD, effects of altitude travel have not been extensively studied. In a study of
32 lowlanders with COPD (median FEV1 59%predicted) ascending from490 to 2590m, a reduction
was observed in the median nocturnal SpO2 from 92% to 85% and emergence of predominantly
central sleep apnea (increase in median AHI from 15.4 to 55.7 events/h).5 This degree of nocturnal
hypoxemia and central sleep apnea was similar to that in patients in the present study with less
severe COPD (placebo group, Table 2) exposed to a higher altitude (3100m). Despite a degree of
hypoxemia in the patients with COPD in the present study similar to that of healthy individuals
studied at 3150m,25 the AHI of patients with COPDwas higher (ie, 39.4 events/h in the present study
during night 1 at 3100mwith placebo vs 7.4 events/h at 3150m). Reduced stability in the control of
breathing of patients with COPD compared with healthy individuals may be due to their older age
and/or lung disease, which might have promoted central apnea by an increased ventilatory drive.26
Figure 2. Effect of Altitude and Dexamethasone on Clinical and Physiologic Outcomes
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A, Mean differences in altitude-induced changes in the first and second nights at 3100m
compared with the corresponding baseline examination at 760m in patients receiving
dexamethasone and placebo. For the top graph, negative changes favor 760m. For the
middle graph, positive changes favor 760m. For the bottom graph, negative changes
favor 760 m. B, Mean differences in altitude-induced changes measured at 3100 m
between patients receiving dexamethasone and placebo (treatment effect of
dexamethasone). For the top graph, positive changes favor dexamethasone. For the
middle graph, negative changes favor dexamethasone. For the bottom graph, positive
changes favor dexamethasone. Subjective sleep quality was assessed by a visual analog
scale (range, 0 [extremely bad] to 100 [excellent]). Error bars indicate 95% CI. ODI
indicates oxygen desaturation index >3% dips in arterial oxygen saturation; SpO2, mean
nocturnal oxygen saturation assessed by pulse oximetry; and TIB, time in bed.
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Because we did not measure ventilatory drive and arterial blood gas analyses are not available from
the previous investigation,25 we are unable to corroborate this hypothesis. The baseline AHI values at
760m of 20.5 and 25.9 events/h in participants of the present study are within the IQR of values
reported in a sample of the general population of individuals older than 40 years (ie, 7.2-27.1
events/h).27 In the absence of symptoms, we have no evidence that the participants in the present
study experienced obstructive sleep apnea syndrome—a condition known to predispose to
exacerbated sleep apnea during altitude sojourns.3
To our knowledge, the present trial is the first to evaluate prevention of altitude-related
nocturnal hypoxemia and breathing disturbances in patients with COPD.We selected
dexamethasone for this trial because it has been shown to prevent AMS in healthy individuals8,9;
furthermore, glucocorticoids are used to treat COPD exacerbations by decreasing airway
inflammation and airflow obstruction.11 Moreover, in otherwise healthy individuals susceptible to
Table 3. Daytime Assessments
Variable
Median (IQR)
Treatment Effect at 3100 m,
Mean Difference (95% CI)Placebo Group (n = 48) Dexamethasone Group (n = 56)
760 m
3100 m
760 m
3100 m
Day 1 Day 2Day 1 Day 2 Day 1 Day 2
Karolinska
sleepiness scorea
3 (3 to 5) 3 (3 to 5)b 3 (3 to 5) 3 (3 to 5) 3 (3 to 5) 3 (3 to 5) −1 (−2 to 0) 0 (−1 to 0)
Reaction time, ms 344 (297 to
422)
327 (286 to
393)
NA 317 (279 to
408)
336 (287 to
401)
NA 38 (−28 to
104)
NA
Weight, kg 73.0 (65.6 to
80.9)
72.1 (65.7 to
79.2)
73.2 (66.0 to
80.2)
72.0 (63.0 to
80.0)
70.5 (62.6 to
80.0)
72.4 (63.3 to
80.7)
0 (−1 to 1) 0 (−1 to 0)
BP, mm Hg
Systolic 131 (111 to
141)
128 (118 to
141)
134 (120 to
142)b
130 (112 to
142)
126 (113 to
134)
129 (120 to
141)
−5 (−10 to 0) −3 (−9 to 3)
Diastolic 82 (73 to 89) 82 (74 to 86) 82 (75 to 89) 79 (73 to 87) 77 (69 to 84)b,c 81 (74 to 85) −5 (−9 to −1) −4 (−7 to 0)
Median (IQR) of
the mean
98 (87 to
105)
96 (89 to
104)
101 (91 to
107)b
95 (87 to
107)
91 (86 to
101)b,c
97 (91 to
104)
−5 (−9 to −1) −3 (−7 to 0)
Heart rate, bpm 64 (59 to 70) 68 (62 to 73)b 66 (60 to 73) 63 (58 to 70) 67 (60 to 71)b 59 (55 to 69)c 0 (−3 to 3) −4 (−7 to −1)
Arterial pH 7.39 (7.38 to
7.41)
7.42 (7.41 to
7.44)b
NA 7.40 (7.39 to
7.42)
7.43 (7.42 to
7.45)b,c
NA 0.01 (0.00 to
0.02)
NA
PaCO2, kPa 5.1 (4.8 to
5.4)
4.6 (4.4 to
4.9)b
NA 5.2 (4.8 to
5.4)
4.4 (4.1 to
4.7)b,c
NA −0.2 (−0.4 to
−0.1)
NA
PaO2, kPa 10.0 (9.2 to 10.7) 8.0 (7.8 to 8.4)b NA 9.6 (9.2 to 10.0) 8.2 (7.9 to 8.7)b NA 0.5 (0.1 to 0.9) NA
SaO2, % 95 (93 to
95)
89 (88 to
90)b
NA 94 (93 to
95)
90 (89 to
91)b,c
NA 0.01 (0.00 to
0.02)
NA
DAaPO2, kPa 3.1 (2.5 to 4.0) 1.1 (0.5 to 1.5)b NA 3.6 (3.0 to 3.9) 1.1 (0.6 to 1.4)b NA −0.2 (−0.6 to 0.2) NA
HCO3, mEq/L 23.3 (21.7 to
24.4)
22.1 (20.8 to
23.0)b
NA 23.2 (22.0 to
24.4)
21.4 (20.6 to
22.8)b
NA −0.6 (−1.4 to
0.1)
NA
Hematocrit, % 44 (40 to 46) 44 (41 to 46) NA 44 (41 to 46) 44 (41 to 47)b NA 0 (0 to 0) NA
Hemoglobin, g/dL 14.8 (13.5 to
15.7)
14.9 (13.8 to
15.6)
NA 15.0 (13.8 to
15.8)
14.9 (14.1 to
16.1)b
NA 0.1 (−0.1 to
0.3)
NA
Glucose, mg/dL 126.1 (108.1 to
144.1)
133.3 (109.9 to
183.2)
NA 120.7 (106.3 to
142.3)
167.6 (140.5 to
205.4)b,c
NA 52.3 (30.6 to
73.9)
NA
FEV1, L 2.7 (2.3 to 3.0) 2.6 (2.3 to 3.0) 2.6 (2.1 to 2.9) 2.5 (1.9 to 2.9) 2.6 (1.9 to 2.9) 2.5 (2.0 to 2.9) 0.1 (0.0 to 0.2) 0.1 (0.0 to 0.2)
% Predicted 96 (77 to 109) 93 (73 to 105) 90 (79 to 105) 85 (73 to 102) 87 (74 to 103) 90 (70 to 100) 3 (−1 to 6) 2 (−2 to 5)
FVC, L 4.3 (3.7 to 4.9) 4.1 (3.5 to 4.8) 4.1 (3.5 to 4.8)b 4.1 (3.3 to 4.5) 4.2 (3.5 to 4.5) 4.0 (3.3 to 4.6) 0.1 (−0.1 to 0.2) 0 (−0.1 to 0.1)
% Predicted 122 (104 to 137) 118 (99 to 136) 121 (102 to 129) 115 (98 to 125) 114 (98 to 125) 115 (97 to 126) 2 (−2 to 5) 0 (−3 to 4)
FEV1/FVC 0.65 (0.60 to
0.68)
0.65 (0.60 to
0.68)
0.65 (0.59 to
0.68)
0.63 (0.56 to
0.66)
0.63 (0.60 to
0.68)b
0.63 (0.58 to
0.68)
0.01 (−0.01 to
0.03)
0.01 (0.00 to
0.03)
Abbreviations: BP, blood pressure; DAaPO2, alveolar-arterial PO2 difference23; FEV1,
forced expiratory volume in the first second of expiration; FVC, forced vital capacity;
HCO3, bicarbonate concentration; IQR, interquartile range; NA, not assessed; PaCO2,
partial pressure of carbon dioxide; PaO2, partial pressure of oxygen; SaO2, arterial oxygen
saturation.
SI conversion factors: to convert glucose tomillimoles per liter, multiply by 0.0555; HCO3
tomillimoles per liter, multiply by 1; hematocrit to proportion of 1.0, multiply by 0.01;
hemoglobin to grams per liter, multiply by 10.
a Karolinska sleepiness score ranges from 1 (extremely alert) to 9 (very sleepy, great
effort to keep alert, fighting sleep).
b P < .05 vs 760m.
c P < .05 between dexamethasone and placebo at the corresponding altitude and day.
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high-altitude pulmonary edema ascending rapidly to 4559m, dexamethasone improved nocturnal
oxygenation and reduced high-altitude periodic breathing in addition to reducing pulmonary artery
pressure.10,28 The reduction in high-altitude periodic breathing was associated with a reduced
eupneic end-tidal PCO2 (the surrogate of PaCO2). As the apnea threshold was also reduced, the CO2
reserve (the difference between eupneic PaCO2 and apnea threshold of PaCO2), one of the
determinants of breathing stability, was maintained. In the present study, patients with COPD
receiving dexamethasone had greater altitude-related hypocapnia than patients receiving placebo.
Assuming no change in the CO2 reserve, the lower AHI at 3100 m in patients receiving
dexamethasonemight therefore be associated with a greater ventilatory overshoot required to cross
the apnea threshold because of the hyperbolic shape of the alveolar ventilation vs PaCO2
relationship.17,29 A reduced hypoxic ventilatory drive owing to the higher PaO2 in patients receiving
dexamethasone might have additionally stabilized their control of breathing. There is increasing
evidence that pulmonary hypertension is associated with breathing instability.30,31 Reducing hypoxic
pulmonary vasoconstriction by the dexamethasone-mediated increase in alveolar ventilation and
alveolar PO2 might have contributed to the reduced AHI level.
The relevance of the improvement in hypoxemia by dexamethasone is uncertain as theminimal
clinically important degree of alleviation of hypoxemia is unknown and symptoms of AMSwere not
reduced.12 However, it is generally accepted that the health risks of hypoxemia increase with its
severity, in particular, in patients with cardiopulmonary disease, such as the participants in the
present study. Air travel recommendations suggest that patients with stable respiratory disease
reaching a SpO2 lower than 85% during a normobaric hypoxic challenge test (breathing 15%
fractional inspired oxygen for 20minutes) use in-flight oxygen.22 For comparison, in the present
study, preventive dexamethasone treatment reduced the proportion of participants with mean
nocturnal SpO2 below 85% bymore than half compared with placebo (25.0% vs 55.2%, P = .001).
In exploratory regression analyses, a low PaO2 (but associated with SpO292% according to
inclusion criteria) and higher values of PaCO2 and AHI at 760mwere associated with more severe
hypoxemia at 3100m—a risk that was reduced by dexamethasone (eTable 2 in Supplement 2).
Moreover, the risk of experiencing an adverse event requiring study termination according to safety
rules was increased nearly 4 times per each 1-kPa reduction in PaO2 at 760 m, but the risk was
reduced 20 times by preventive dexamethasone treatment (eTable 3 in Supplement 2).
The improvement of subjective sleep quality with dexamethasone during night 2 at 3100m (12
mmon the visual analog scale) was similar to the difference of 10mm found to be clinically important
in patients with insomnia.32 Subjective sleepiness and psychomotor vigilance test reaction time
remained unchanged with ascent to a higher altitude (Table 3). It is uncertain whether themild
altitude-induced reduction in cerebral tissue oxygenation detected by near-infrared spectroscopy
was not strong enough to causemeasurable effects in these outcomes in both patient groups.
A total of 16 (27.6%) of the patients with COPD assigned to dexamethasone had drug-induced
hyperglycemia.33 No other relevant adverse effects of the short-term use of dexamethasone were
noted in the present study.
Limitations
Limitations of the present trial include the population with predominantly mild COPD during 2 nights
at altitude. The results can therefore not be extrapolated to patients with more severe COPD and
longer altitude sojourns. Because this study was performed in residents of Central Asia it is uncertain
whether the results apply to people in other regions of theworld. Nevertheless, our analyses suggest
that severe hypoxemia assessed by the PaO2 at low altitude (but not by pulse oximetry, which may
overestimate arterial oxygen saturation in smokers with elevated carboxyhemoglobin levels), higher
levels of PaCO2, and sleep apnea may help to identify patients with more severe COPD at risk of
experiencing adverse health effects at high altitudes (eTables 2-4 in Supplement 2).
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Conclusions
The results of the present randomized clinical trial reveal that lowlanders with mild to moderate
COPD traveling to high altitude experienced nocturnal hypoxemia and central sleep apnea.
Preventive treatment with dexamethasone reduced the risk of severe hypoxemia and/or adverse
events requiring premature descent to lower altitude. Because dexamethasone predisposes to
hyperglycemia, its use for prevention of altitude-related hypoxemia, as well as breathing and sleep
disturbances in patients with COPD, should be limited. We suggest that a short course of preventive
dexamethasone treatment be considered only in patients with COPDwho do not have diabetes or
uncontrolled cardiovascular disease and are not heavy smokers. In addition, treatment should be
considered if the evaluation before ascent showsmoderate hypoxemia (reduced PaO2 but SpO2
92%), and a PaCO2 value that is in the high normal range, and oxygen therapy during high-altitude
travel is not feasible.
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